Tel Aviv-yafo, Israel
Tel Aviv-yafo, Israel
SEARCH FILTERS
Time filter
Source Type

BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


News Article | June 1, 2017
Site: globenewswire.com

SYDNEY, Australia, May 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer of Prima, said: “Securing such a distinguished group of medical professionals is a testament to the growing level of support for immuno-oncology product candidates. While the initial focus of the board will be on developing IMP321 in metastatic breast cancer worldwide, it will also advise us on our other clinical and pre-clinical programs.” The newly formed board will be chaired by Pr. Martine Piccart, who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin Al-Batran. Professor Martine J. Piccart is professor of oncology at the Université Libre de Bruxelles (ULB) and Head of the medicine department at the Institute Jules Bordet, in Brussels, Belgium. With a primary interest in breast cancer (BC) and drug development, Prof. Piccart is a leader in international research collaboration and is the co-principal investigator of several large clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Breast International Group (BIG) which unites more than 50 BC research groups around the world. Prof. Piccart is the immediate past president of the European CanCer Organisation (ECCO, 2014-2015). She has also held presidencies of the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO), and has served on the American Society of Clinical Oncology Board (ASCO). She joined the Board of Directors of the AACR in 2017. Doctor Luc Dirix is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp, Belgium. He is a member of the American Society for Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer. He is past-chairman and current Board member of the Belgian Society of Medical Oncology. Professor David Cameron is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research Centre in the UK. He is a member of the American Society of Clinical Oncology & the European Society for Medical Oncology, and is active in a number of clinical trials in breast cancer in the UK and other countries. Doctor Samson Fung of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including Novartis and Bristol-Myers-Squibb. Dr. Fung is the CEO & Managing Director of Volvox Therapeutics and a member of the American Society of Clinical Oncology, the American Society of Clinical Haematology & the German Society of Pharmaceutical Medicine. Professor Salah-Eddin Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany. As a haematologist and oncologist, Prof. Al-Batran is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials. He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organisation for Research and Treatment of Cancer. About IMP321 IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


News Article | June 1, 2017
Site: globenewswire.com

SYDNEY, Australia, May 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer of Prima, said: “Securing such a distinguished group of medical professionals is a testament to the growing level of support for immuno-oncology product candidates. While the initial focus of the board will be on developing IMP321 in metastatic breast cancer worldwide, it will also advise us on our other clinical and pre-clinical programs.” The newly formed board will be chaired by Pr. Martine Piccart, who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin Al-Batran. Professor Martine J. Piccart is professor of oncology at the Université Libre de Bruxelles (ULB) and Head of the medicine department at the Institute Jules Bordet, in Brussels, Belgium. With a primary interest in breast cancer (BC) and drug development, Prof. Piccart is a leader in international research collaboration and is the co-principal investigator of several large clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Breast International Group (BIG) which unites more than 50 BC research groups around the world. Prof. Piccart is the immediate past president of the European CanCer Organisation (ECCO, 2014-2015). She has also held presidencies of the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO), and has served on the American Society of Clinical Oncology Board (ASCO). She joined the Board of Directors of the AACR in 2017. Doctor Luc Dirix is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp, Belgium. He is a member of the American Society for Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer. He is past-chairman and current Board member of the Belgian Society of Medical Oncology. Professor David Cameron is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research Centre in the UK. He is a member of the American Society of Clinical Oncology & the European Society for Medical Oncology, and is active in a number of clinical trials in breast cancer in the UK and other countries. Doctor Samson Fung of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including Novartis and Bristol-Myers-Squibb. Dr. Fung is the CEO & Managing Director of Volvox Therapeutics and a member of the American Society of Clinical Oncology, the American Society of Clinical Haematology & the German Society of Pharmaceutical Medicine. Professor Salah-Eddin Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany. As a haematologist and oncologist, Prof. Al-Batran is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials. He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organisation for Research and Treatment of Cancer. About IMP321 IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

Loading imp Inc collaborators
Loading imp Inc collaborators